帕博利珠单抗用于体能状态2分的非小细胞肺癌患者(PePS2):单臂2期试验
PePS2是一项在英国10家医院开展的多中心、单臂、开放标签2期试验,纳入严格判定为PS2的NSCLC患者,给予帕博利珠单抗200 mg每3周,按肿瘤比例评分(TPS)和治疗线数分层评估。60例可评估患者中,持续临床获益(DCB)在一线为38%(95%CI 21-57),后线为36%(22-52);TPS<1%为22%(11-41),TPS 1-49%为47%(25-70),TPS≥50%为53%(30-75)。毒性发生率为28%(19-41),无5级治疗相关不良事件,无因超进展导致的早期死亡。作者认为帕博利珠单抗可安全用于PS2患者,疗效至少与PS0-1相当,为临床将该药纳入PS2患者治疗路径提供了信心。
要点
- 严格判定为PS2的NSCLC患者接受帕博利珠单抗200 mg每3周,毒性发生率28%(95%CI 19-41),无5级治疗相关不良事件。
- DCB在一线患者为38%(95%CI 21-57),后线患者为36%(22-52)。
- DCB随TPS升高而增加:TPS<1%为22%(11-41),TPS 1-49%为47%(25-70),TPS≥50%为53%(30-75)。
- 毒性导致剂量延迟者11/60(18%),导致停药者6/60(10%);最常见3-4级不良事件为呼吸困难(n=9)、低钠血症(n=5)、厌食(n=4)。
- 作者认为帕博利珠单抗可安全用于PS2的NSCLC患者,疗效至少与PS0-1患者相当。
适用人群与场景
- 英国10家医院纳入的NSCLC患者,经严格判定为PS2。
- 按TPS分层(<1%、1-49%、≥50%)和按治疗线数分层(一线、后线)。
诊断标准与关键阈值
- 体能状态(PS)2分,采用严格归属判定。
- 肿瘤比例评分(TPS)分层界值:<1%、1-49%、≥50%。
处置流程与药物剂量
- 帕博利珠单抗200 mg,每3周一次,静脉给药(原文未写明途径,按药物常规为静脉给药,但原文摘要未明确,故不写途径)。
- 持续临床获益(DCB)定义:出现完全缓解、部分缓解或疾病稳定并持续至至少第18周计划的第二次CT扫描。
- 毒性定义:任何时候因不良事件发生治疗相关剂量延迟或治疗中止。
研究设计与关键结果
- 多中心、单臂、开放标签2期试验,在英国10家医院开展,纳入62例,60例可评估共同主要终点;中位年龄72岁(IQR 65-75),男性33例(55%),女性27例(45%)。
- DCB观察发生率:一线患者38%(95%CI 21-57,n=24),后线患者36%(22-52,n=36)。
- DCB按TPS:<1%为22%(11-41,n=27),1-49%为47%(25-70,n=15),≥50%为53%(30-75,n=15);模型估计也显示DCB随TPS增加。
- 毒性发生率28%(95%CI 19-41);剂量延迟11/60(18%),停药6/60(10%)。
- 无5级治疗相关不良事件,无因超进展导致的早期死亡;最常见3-4级不良事件为呼吸困难(n=9)、低钠血症(n=5)、厌食(n=4)。
- 治疗相关严重不良事件10例:腹泻3例,急性肾损伤、肾上腺功能不全、高胆红素血症、口腔黏膜炎、皮疹、尿路感染、呕吐各1例。
证据类型、等级与局限
- 证据类型:多中心、单臂、开放标签2期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,帕博利珠单抗可安全用于PS2的NSCLC患者,未增加免疫相关或其他毒性风险。
- 作者认为,PS2患者的疗效结局至少与PS0-1患者相当,数据为临床医生将帕博利珠单抗纳入PS2患者治疗路径提供了信心。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Therapeutic blockade of the axis of programmed cell death 1 (PD-1) and its ligand (PD-L1) has transformed the management of non-small-cell lung cancer (NSCLC). Clinical trials with pembrolizumab have enrolled patients with performance status (PS) 0-1. However, around 18% of patients with NSCLC are PS2, and the activity and safety of pembrolizumab in these patients is unclear. We aimed to evaluate the safety and efficacy of pembrolizumab in these patients.
METHODS: We did a multicentre, single-arm, open-label, phase 2 trial (PePS2) in ten hospitals in the UK, in which patients with NSCLC and a rigorous ascription of PS2 were given pembrolizumab 200 mg every 3 weeks. No masking was used in this trial. We stratified the treatment evaluation by tumour proportion score (TPS) and line of therapy. Co-primary outcomes were: (1) durable clinical benefit (DCB), defined as the occurrence of complete response, partial response, or stable disease that continues until at least the second CT scan scheduled at 18 weeks; and (2) toxicity, defined as the occurrence at any time of treatment-related dose delay or treatment discontinuation due to an adverse event. Analysis included all patients who received any pembrolizumab. As well as reporting simple observed incidence for the co-primary outcomes, DCB and toxicity, we also estimated incidence using a model-based method for correlated binary outcomes. This study is registered with ClinicalTrials.gov, NCT02733159; EudraCT, 2015-002241-55; and ISRCTN, 10047797.
FINDINGS: Between Jan 4, 2017, and Feb 13, 2018, of 112 patients assessed for eligibility, we recruited 62 patients. 60 patients were evaluable for the co-primary outcomes. Median age was 72 years (IQR 65-75); 33 (55%) of participants were male and 27 (45%) were female. The observed incidence for DCB was 38% (95% CI 21-57) in first-line patients (n=24) and 36% (22-52) in subsequent-line patients (n=36); DCB was 22% (11-41) in patients with a TPS less than 1% (n=27), 47% (25-70) in patients with a TPS of 1-49% (n=15), and 53% (30-75) in patients with a TPS of 50% or greater (n=15). An increase in DCB incidences with TPS was also shown in model-based estimates. Toxicity was observed in 28% (95% CI 19-41) of patients, 11 (18%) of 60 due to dose delay and 6 (10%) of 60 due to drug discontinuation. No grade 5 treatment-related adverse events were observed and no early deaths were attributed to hyperprogression. The most common grade 3-4 adverse events were dyspnoea (n=9), hyponatraemia (n=5), and anorexia (n=4). There were ten serious adverse events considered to be related to treatment, comprising diarrhoea (n=3) and acute kidney injury, adrenal insufficiency, hyperbilirubinaemia, oral mucositis, rash, urinary tract infection, and vomiting (n=1 each).
INTERPRETATION: Patients with NSCLC of PS2 are a group of patients of unmet therapeutic need. The PePS2 trial shows that pembrolizumab can be safely administered to these patients, with no increase in the risk of immune-related or other toxicities. Efficacy outcomes are at least as good as those in patients with PS0-1 and the data provides clinicians with the confidence to incorporate pembrolizumab into the treatment pathway of patients with NSCLC of PS2.
FUNDING: Merck, Sharp & Dohme.
参考来源
- Middleton G, Brock K, Savage J, et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020. PMID: 32199466. doi:10.1016/S2213-2600(20)30033-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。